Trial Profile
A Phase 1, Open-label, Randomized, Crossover Study in 20 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Raltegravir, Both at Steady-state
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2012
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C; HIV infections
- Focus Pharmacokinetics
- Sponsors Janssen Infectious Diseases BVBA
- 04 Nov 2011 Actual initiation date changed from Jan 2011 to Dec 2010 as reported by ClinicalTrials.gov.
- 02 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.